Objectives:

The general objective of the project is to improve the quality of life of celiac patients through the implementation of automated technologies in the clinical field.

This objective is specified in the following technical goals:

  1. Develop a new methodology, using automated immunoassays, for the determination of GIP in urine and stool.
  2. Validate this development as an effective method for monitoring celiac disease.
  3. Assess the clinical utility of this technical development in measuring intestinal permeability.

Consortium: BIOMEDAL, S.L. (ES) – ALPCO LTD (U.S.)

File Identification Number: EXP – 00170842 / PAIS-20241025

Project Acronym: GLUTENEXT